Cyclerion (CYCN): Price to Sales

Brandmark of Cyclerion (CYCN)

Cyclerion Therapeutics (CYCN) minimizes risks by developing drugs for rare vascular and neurological pathologies. The price-to-sales ratio visualizes the current business valuation, where the parameter value equals 7.50. System stability is ensured by the monetization of intellectual property within a binary pipeline. Process sustainability and strict ethical control in laboratories complement the company's development strategy.

CYCN (Cyclerion Therapeutics Inc.) Market Cap to Revenue history from 07/04/2022 to 09/09/2026

Analytical breakdowns for Cyclerion Therapeutics Inc. (CYCN)

General company analysis:CYCN - Cyclerion Therapeutics
Brand item of Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics (CYCN) operates as a research and development center, outsourcing manufacturing processes and clinical trials to third-party contractors to optimize costs. An analysis of the price-to-sales multiple allows for the correlation of market capitalization with actual sales volume, determining the degree of overvaluation of the asset and assessing the sustainability of current quotes relative to the cash flow generated by the business.

Competitors of Cyclerion Therapeutics

BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|AVXL: P/S Multiple|CBLL (ceribell.com) - Price-to-Revenue Ratio|PRTA (Prothena Corporation) - P/S Multiple|Market Cap to Revenue alector.com (ALEC)|Price-to-Revenue Ratio Annexon, Inc. (ANNX)|OMER - Price to Sales|P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Price to Sales|Voyager Therapeutics Inc - P/S Multiple|Neumora (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue cogrx.com (CGTX)|Price-to-Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Price-to-Revenue Coefficient Cassava Sciences|P/S Multiple ASRT (Assertio Holdings)|COYA - Market Cap to Revenue|vistagen.com - P/S Multiple|OVID: Price-to-Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Revenue Ratio|CervoMed Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Price-to-Revenue Coefficient|Market Cap to Revenue PEPG (PepGen Inc)|P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Revenue Ratio|KLTO: P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - P/S Multiple|Price-to-Revenue Ratio Reviva Pharmaceuticals, Inc.|Market Cap to Revenue metaviatx.com (MTVA)|P/S Multiple NRXS|HSDT - Price to Sales|Passage Bio, Inc. - Market Cap to Revenue|bionomics.com.au (NEUP) - Price to Sales|Minerva - P/S Multiple|Market Capitalization-to-Revenue Ratio ATHA (Athira Pharma Inc)|ADXN: P/S Multiple|Market Cap to Revenue Ratio ALZN|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue